deltatrials
Terminated PHASE2 INTERVENTIONAL NCT00280072

Study to Evaluate the Safety and Efficacy of the Renal Assist Device in Patients With Acute Renal Failure

A Multi-Center, Randomized, Controlled, Double-Blind, Phase II Study To Assess Safety and Efficacy With the Renal Assist Device (RAD) in Patients With Acute Renal Failure

Sponsor: RenaMed Biologics

Interventions Renal Assist Device
Updated 6 times since 2017 Last updated: Nov 29, 2012 Started: Jan 31, 2006 Primary completion: Aug 31, 2007 Completion: Aug 31, 2007
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

This trial was terminated. No reason was provided.

A PHASE2 clinical study on Kidney Failure, Acute, this trial is terminated or withdrawn. The trial is conducted by RenaMed Biologics and has accumulated 6 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotTerminated~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotTerminated~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 12 months · monthly snapshotTerminated

Change History

6 versions recorded
  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

Show 1 earlier version
  1. Jan 2017 — Jun 2018 [monthly]

    Terminated PHASE2

    First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • RenaMed Biologics
Data source: RenaMed Biologics

For direct contact, visit the study record on ClinicalTrials.gov .